Phase 3 SAFFRON data support EU and Japanese filings for savolitinib plus osimertinib in EGFR-mutated NSCLC with MET overexpression or amplification.
Related to this article
The EMA validated the marketing authorization application for varegacestat in adults with desmoid tumors.
The NMPA has accepted a supplemental application for subcutaneous toripalimab plus disitamab vedotin in first-line HER2-expressing urothelial carcinoma, following the May 2026 approval of the intravenous combination.
Advertisement
Advertisement
Trending on OncLive
1
Roswell Park Researchers Identify Strategy for Overcoming Resistance to RAS-Targeted Cancer Drugs
2
Tocilizumab Prophylaxis, Caregiver Readiness, and Chair Time Shape Community Bispecific Programs in R/R Myeloma
3
How Biomarkers Now Drive First-Line Therapy in mHSPC
4
Coordinating the Timing of Interventions in NETs
5